Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference.

Presentation details
Format: Fireside Chat
Date: Thursday, June 8, 2023
Time: 11:30 a.m.-11:55 a.m., EDT        

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in the US and EU (NCT05369000). A Phase 1/2a dose escalation clinical study to evaluate LAVA-051, for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is also enrolling patients in the EU and US (NCT04887259). The Company has a license agreement with Seagen for the development of SGN-EGFRd2 (LAVA-1223). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedInTwitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.